← Back to Search

PD-L1 Inhibitor

Plinabulin + Radiation/Immunotherapy for Cancer

Phase 1 & 2
Recruiting
Led By Vivek Subbiah
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least one additional non-contiguous lesion that has not been irradiated amenable to radiographic evaluation
Age >= 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Study Summary

This trial is studying the side effects and best dose of plinabulin when given with radiation therapy and immunotherapy to patients with advanced cancer that has progressed after treatment with PD-1 or PD-L1 targeted antibodies.

Who is the study for?
This trial is for adults with certain advanced cancers that have worsened after treatment with PD-1 or PD-L1 inhibitors. Participants must be in fair health (ECOG 0-2), have at least one tumor suitable for radiation, and adequate organ function. Pregnant women, those with recent major surgery, uncontrolled infections, or heart disease are excluded.Check my eligibility
What is being tested?
The study is testing the combination of plinabulin (a drug that targets blood vessels to tumors) with radiation therapy and immunotherapy drugs like Pembrolizumab. The goal is to find the best dose of plinabulin and see if this combo can better treat advanced cancers than current methods.See study design
What are the potential side effects?
Possible side effects include reactions related to immune system changes such as inflammation in organs, fatigue, digestive issues from radiation therapy, blood cell count changes due to plinabulin, and typical risks associated with immunotherapies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have at least one cancer spot that hasn't been treated with radiation and can be seen on scans.
Select...
I am 18 years old or older.
Select...
I have mostly recovered from my last treatment, except for hair loss.
Select...
My cancer progressed despite previous immunotherapy treatments.
Select...
I am able to get out of my bed or chair and move around.
Select...
I have a cancer lesion that can be treated with radiation.
Select...
I have recovered from any major surgery I had at least 4 weeks ago.
Select...
My kidney function, measured by GFR, is at least 30 mL/min.
Select...
My sample for testing was recently taken with a needle biopsy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events (AEs)
Objective tumor response rate (ORR) (complete response + partial response)
Secondary outcome measures
Disease control rate (complete response, partial response + stable disease)
Overall survival
Progression-free survival

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm A (radiation therapy, plinabulin, immunotherapy)Experimental Treatment7 Interventions
Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients receive plinabulin IV over 30-60 minutes on days 1 and 4 of cycle 1, days 1 and 4 of cycle 2 (if receiving radiation therapy in cycle 2), and day 1 and or 15 (any day receiving immunotherapy) of subsequent cycles. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
Group II: Arm B (radiation therapy, immunotherapy)Active Control6 Interventions
Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
2017
Completed Phase 3
~5860
Nivolumab
2014
Completed Phase 3
~4750
Radiation Therapy
2017
Completed Phase 3
~7250
Avelumab
2018
Completed Phase 2
~2450
Plinabulin
2017
Completed Phase 3
~280
Durvalumab
2017
Completed Phase 2
~3870
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,967 Previous Clinical Trials
1,804,790 Total Patients Enrolled
Vivek SubbiahPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
327 Total Patients Enrolled
Siqing Fu, MD, PHDPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
121 Total Patients Enrolled

Media Library

Atezolizumab (PD-L1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04902040 — Phase 1 & 2
Cancer Research Study Groups: Arm B (radiation therapy, immunotherapy), Arm A (radiation therapy, plinabulin, immunotherapy)
Cancer Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT04902040 — Phase 1 & 2
Atezolizumab (PD-L1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04902040 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What health conditions is Plinabulin most commonly employed to address?

"Plinabulin is commonly prescribed to fight malignant neoplasms, however it has also been used for patients with microsatellite instability high and squamous cell carcinoma. Additionally, it may be beneficial in treating unresectable melanomas."

Answered by AI

What is unique about this research undertaking?

"Currently, there are 2384 Plinabulin trials happening in 79 different countries across 4231 cities. The very first trial conducted was sponsored by Hoffmann-La Roche and tested 720 patients during its Phase 2 approval stage back in 2008. Since then, 821 other studies have been launched."

Answered by AI

What is the aggregate amount of participants in this clinical investigation?

"Affirmative. According to the clinicaltrials.gov listing, this medical trial is actively enrolling members and was first posted on April 14th 2021. The experiment requires 12 individuals from one center in total."

Answered by AI

Are there any open enrollments for this trial presently?

"According to clinicaltrials.gov, this research is actively searching for participants as of now. This trial was first announced on April 14th 2021 and has been updated as recent as June 29th 2022."

Answered by AI
~3 spots leftby Jun 2025